Healthy BMI tied to lower type 1 diabetes progression risk

For 833 people already showing an autoimmune warning sign for type 1 diabetes, the next few years carried a different statistical pattern when their weight range changed. A Baylor College of Medicine-led team found that participants who moved from overweight or obesity into the normal body mass index range had about a 48% lower risk of progressing to clinical disease than those who stayed in the higher ranges.

The participants were part of TrialNet, a type 1 diabetes prevention study, and all had islet autoantibodies — blood markers showing that the immune system was attacking the insulin-producing cells of the pancreas. The researchers followed them for about 4 years. During that period, about 27% entered the normal BMI range.

The association was not evenly distributed. It was strongest in boys younger than 12 years and girls ages 12–17, while BMI normalization was not clearly linked to lower progression risk in adults. Type 1 diabetes is an autoimmune disease: as insulin-producing cells are damaged, the body loses the hormone needed to use sugar circulating in the blood for energy.

For families and clinicians, the practical message is a research lead, not a prescription. In children, reaching a normal BMI does not necessarily mean losing weight; it may happen as weight gain slows or stabilizes while the child grows taller. A healthy weight trajectory could become part of efforts to study whether progression can be delayed, alongside early identification and approved therapies that already exist for some people at increased risk.

The boundary is clear. This was an observational study, so it found an association rather than proving that lowering BMI prevents or delays type 1 diabetes. The Baylor team is calling for a prospective intervention trial to test that possibility, and the reasons for the stronger signal in youth remain under investigation.